نتایج جستجو برای: thalidomide

تعداد نتایج: 3195  

Journal: :European journal of heart failure 2006
Arne Yndestad Leif Erik Vinge Reidar Bjørnerheim Thor Ueland Jacob E Wang Stig S Frøland Håvard Attramadal Pål Aukrust Erik Oie

BACKGROUND Inflammation plays a pathogenic role in the development of heart failure (HF). The aim of this study was to examine the effect of treatment with the immunomodulating drug thalidomide in a rat model for post-myocardial infarction (MI) HF. METHODS Rats were subjected to MI by left coronary artery ligation or sham-operated. Seven days after surgical intervention rats were randomised t...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2004
Seung-Jung Park Hyo-Soo Kim Han-Mo Yang Kyung-Woo Park Seock-Won Youn Soo-In Jeon Dae-Hee Kim Bon-Kwon Koo In-Ho Chae Dong-Joo Choi Byung-Hee Oh Myoung-Mook Lee Young-Bae Park

OBJECTIVE Inflammation is one of the main pathogeneses of neointimal hyperplasia after coronary intervention. Thalidomide, because of its potent antiinflammatory and immunomodulatory properties, is being re-evaluated in several clinical fields. Therefore, we examined whether thalidomide therapy affects neointimal formation. METHODS AND RESULTS In male Sprague-Dawley rats, 100 mg/kg of either ...

Journal: :The Journal of pharmacology and experimental therapeutics 2001
J P Drenth A G Vonk A Simon R Powell J W van der Meer

Hyper-IgD and periodic fever syndrome (HIDS) is an autosomal recessive disorder featured by recurrent febrile attacks. Previous unpublished experience (J. van der Meer and R. Powell) suggested that thalidomide may prevent febrile attacks. Six HIDS patients (5 male and 1 female) who had at least one febrile attack every 6 weeks, entered a randomized, double-blind, placebo-controlled crossover tr...

2017
Etsuko Tokunaga Hidehiko Akiyama Vadim A Soloshonok Yuki Inoue Hideaki Hara Norio Shibata

Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma. However, besides its undesirable teratogenic side effect, its configurational instability critically limits any further therapeutic improvements of this drug. In 1999, we developed fluoro-thalidomide which is a bioisostere of thalidomide, but, in...

Journal: :Blood 2010
Henk M Lokhorst Bronno van der Holt Sonja Zweegman Edo Vellenga Sandra Croockewit Marinus H van Oers Peter von dem Borne Pierre Wijermans Ron Schaafsma Okke de Weerdt Shulamiet Wittebol Michel Delforge Henriëtte Berenschot Gerard M Bos Kon-Siong G Jie Harm Sinnige Marinus van Marwijk-Kooy Peter Joosten Monique C Minnema Rianne van Ammerlaan Pieter Sonneveld

The phase 3 trial HOVON-50 was designed to evaluate the effect of thalidomide during induction treatment and as maintenance in patients with multiple myeloma who were transplant candidates. A total of 556 patients was randomly assigned to arm A: 3 cycles of vincristine, adriamycin, and dexamethasone, or to arm B: thalidomide 200 mg orally, days 1 to 28 plus adriamycin and dexamethasone. After i...

Journal: :Blood 2007
Wulin Aerbajinai Jianqiong Zhu Zhigang Gao Kyung Chin Griffin P Rodgers

Although thalidomide has been shown to improve anemia in some patients with myelodysplastic syndromes and stimulates erythropoietin in patients with multiple myeloma, thalidomide's specific effects on gamma-globin gene expression during erythroid differentiation have not been studied. Here, we investigated the effects of thalidomide on gamma-globin gene expression and the involved signaling pat...

Journal: :Cadernos de saude publica 2014
Francisco J R Paumgartten

Thalidomide was banned worldwide in the 1960s due to its teratogenicity, and remained so until the late 1990s when it returned to physicians’ armamentarium as a medicine for a variety of inflammatory diseases and hematological malignancies that were difficult to treat. A landmark event in this resurgence was the discovery that thalidomide inhibited angiogenesis in the rabbit cornea micropocket ...

Journal: :Biological & pharmaceutical bulletin 2002
Megan G Marks Jiandong Shi Michael O Fry Zili Xiao Michelle Trzyna Vedavalli Pokala Michael A Ihnat Pui-Kai Li

Angiogenesis, in particular anti-angiogenesis, is an area of particular therapeutic interest in cancer treatment. Several anti-angiogenic agents are in the final stages of clinical trials. One of these agents, thalidomide, best known for its teratogenic potential, is showing promise against several tumor types. Thalidomide has been shown previously to require bio-activation to exert its anti-an...

Journal: :The Journal of pharmacology and experimental therapeutics 2002
Jason M Hansen Katie K Harris Martin A Philbert Craig Harris

Thalidomide produces numerous birth defects, the most notable being phocomelia. Mechanisms behind thalidomide-induced malformations have not been fully elucidated, although recent evidence suggests a role for reactive oxygen species. A thalidomide-resistant (rat) and -sensitive (rabbit) species were used to compare potential inherent differences related to oxidative stress that may provide a mo...

2017
Tânia R.C. Vergara Sadia Samer Joanna R. Santos-Oliveira Leila B. Giron Muhammad Shoaib Arif Maria Luciana Silva-Freitas Lia A. Cherman Mauro S. Treitsman Alberto Chebabo Maria Cecilia A. Sucupira Alda M. Da-Cruz Ricardo Sobhie Diaz

TRIAL DESIGN Open-label, randomised, controlled, pilot proof-of-concept clinical trial. METHODS Participants: Antiretroviral naïve adult males with CD4 count ≥350cells/mm3. INTERVENTIONS Patients were randomised to receive thalidomide 200mg QD for 3weeks (Thalidomide group) or not (Control group) and followed for 48weeks. OBJECTIVE We hypothesized that short-term Thalidomide use would red...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید